Clinical Trial Detail

NCT ID NCT02985957
Title A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.